



# Ongoing Clinical Trials by Phase and Therapeutic Approach



1. Within-graph labels represent phase totals


2. Trials may employ multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to phase totals

# Ongoing Clinical Trials by Phase and Region




1. Within-graph labels represent phase totals
2. Clinical trials take place in multiple regions; sum of regional totals will not be equivalent to phase totals

# Ongoing Clinical Trials by Phase and Sponsor




1. Within-graph labels represent phase totals  
2. Non-industry includes academic and government sponsors

# Ongoing Clinical Trials by Phase and Prevalence




1. Within-graph labels represent phase totals

# Ongoing Clinical Trials by Phase and Oncology Indication & Tumor Type




1. Within-graph labels represent phase totals

# Ongoing Clinical Trials by Therapeutic Approach and Phase



1. Within-graph labels represent therapeutic approach totals


# Ongoing Clinical Trials by Therapeutic Approach and Region



1. Within-graph labels represent therapeutic approach totals

2. Clinical trials take place in multiple regions; sum of regional totals will not be equivalent to therapeutic approach totals


# Ongoing Clinical Trials by Therapeutic Approach and Sponsor



1. Within-graph labels represent therapeutic approach totals  
2. Non-industry includes academic and government sponsors




# Ongoing Clinical Trials by Therapeutic Approach and Prevalence



1. Within-graph labels represent therapeutic approach totals

# Ongoing Clinical Trials by Therapeutic Approach and Oncology Indication & Tumor Type



1. Within-graph labels represent therapeutic approach totals

# Methodology Notes for Clinical Trial Data

## Methodology Notes

1. Clinical trial data represent a snapshot in time; this snapshot was taken in August 2023.
2. Clinical trials include trials in phases 1-3, active at any point in the calendar year.
3. Clinical trial regions are based on known site locations, which may change over time.
4. Clinical trials may have multiple site locations which may reside in a single region or span across multiple regions; the sum of clinical trials across regions will not be equivalent to the total number of trials.
5. \*Trial sponsorship is based on GlobalData's categorization of entities: Industry = public or private entities; Nonindustry = government entities or institutions such as hospitals, medical centers, and facilities funded by not-for-profits.
6. \*Oncology and prevalence classifications are based on GlobalData identification of trial indications; many trials have multiple indications.
7. GlobalData's classification of 'rare' indications or populations is based on US FDA and HIG Genetic and Rare Diseases Information Center (GARD) definitions (affecting <200,000 people in the US); 'rare' may not reflect different regional prevalences.

\*Updated in 2023